File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.vaccine.2008.05.042
- Scopus: eid_2-s2.0-50849096413
- PMID: 18945415
- WOS: WOS:000260323100008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan
Title | Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan |
---|---|
Authors | |
Keywords | Asia Pacific Cervical cancer Epidemiology Hong Kong HPV Singapore Taiwan |
Issue Date | 2008 |
Publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine |
Citation | Vaccine, 2008, v. 26 SUPPL. 12, p. M60-M70 How to Cite? |
Abstract | Hong Kong, Singapore and Taiwan are three island states that are newly emerged affluent economic areas in Asia. The majority of the populations are ethnically Chinese with a total population of 6.98, 4.5 and 23 million, respectively. Cervical cancer has been declining over the last thirty years in all three states and is largely attributable to widespread opportunistic cervical cancer screening. The age-standardized incidence rates of cervical cancer are 9.6 per 100,000 women in Hong Kong in 2004, 10.6 per 100,000 women in Singapore in 2002 and 18.6 per 100,000 women in Taiwan in 2003. High prevalence of human papillomavirus (HPV) was observed in all three states. In cervical cancer, HPV 16 and 18 are the two most prevalent HPV types, but HPV 58 and 52 are also highly prevalent in these three states. Important epidemiological risk factors for invasive cervical cancer include smoking and age at sexual debut for women, although this is changing towards an earlier age. Of the three states, Taiwan was the first to have a comprehensive national screening programme in 1995 followed by Hong Kong in 2002 and Singapore in 2004. Women in these three states are well aware of cervical cancer and the preventative means by Pap smear screening, although their awareness and understanding of the role of HPV in cervical carcinogenesis is low. Prophylactic HPV vaccines have been licensed in the three states. Routine comprehensive public vaccination programme for adolescent girls has yet to be adopted by the governmental agency, despite an affirmative recommendation by medical professional bodies. © 2008 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/60371 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.342 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tay, SK | en_HK |
dc.contributor.author | Ngan, HYS | en_HK |
dc.contributor.author | Chu, TY | en_HK |
dc.contributor.author | Cheung, ANY | en_HK |
dc.contributor.author | Hseon Tay, E | en_HK |
dc.date.accessioned | 2010-05-31T04:09:18Z | - |
dc.date.available | 2010-05-31T04:09:18Z | - |
dc.date.issued | 2008 | en_HK |
dc.identifier.citation | Vaccine, 2008, v. 26 SUPPL. 12, p. M60-M70 | en_HK |
dc.identifier.issn | 0264-410X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/60371 | - |
dc.description.abstract | Hong Kong, Singapore and Taiwan are three island states that are newly emerged affluent economic areas in Asia. The majority of the populations are ethnically Chinese with a total population of 6.98, 4.5 and 23 million, respectively. Cervical cancer has been declining over the last thirty years in all three states and is largely attributable to widespread opportunistic cervical cancer screening. The age-standardized incidence rates of cervical cancer are 9.6 per 100,000 women in Hong Kong in 2004, 10.6 per 100,000 women in Singapore in 2002 and 18.6 per 100,000 women in Taiwan in 2003. High prevalence of human papillomavirus (HPV) was observed in all three states. In cervical cancer, HPV 16 and 18 are the two most prevalent HPV types, but HPV 58 and 52 are also highly prevalent in these three states. Important epidemiological risk factors for invasive cervical cancer include smoking and age at sexual debut for women, although this is changing towards an earlier age. Of the three states, Taiwan was the first to have a comprehensive national screening programme in 1995 followed by Hong Kong in 2002 and Singapore in 2004. Women in these three states are well aware of cervical cancer and the preventative means by Pap smear screening, although their awareness and understanding of the role of HPV in cervical carcinogenesis is low. Prophylactic HPV vaccines have been licensed in the three states. Routine comprehensive public vaccination programme for adolescent girls has yet to be adopted by the governmental agency, despite an affirmative recommendation by medical professional bodies. © 2008 Elsevier Ltd. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine | en_HK |
dc.relation.ispartof | Vaccine | en_HK |
dc.subject | Asia Pacific | en_HK |
dc.subject | Cervical cancer | en_HK |
dc.subject | Epidemiology | en_HK |
dc.subject | Hong Kong | en_HK |
dc.subject | HPV | en_HK |
dc.subject | Singapore | en_HK |
dc.subject | Taiwan | en_HK |
dc.title | Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=26 Suppl. 12&spage=M60&epage=M70&date=2008&atitle=Epidemiology+of+human+papillomavirus+infection+and+cervical+cancer+and+future+perspectives+in+Hong+Kong,+Singapore+and+Taiwan | en_HK |
dc.identifier.email | Ngan, HYS:hysngan@hkucc.hku.hk | en_HK |
dc.identifier.email | Cheung, ANY:anycheun@hkucc.hku.hk | en_HK |
dc.identifier.authority | Ngan, HYS=rp00346 | en_HK |
dc.identifier.authority | Cheung, ANY=rp00542 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.vaccine.2008.05.042 | en_HK |
dc.identifier.pmid | 18945415 | - |
dc.identifier.scopus | eid_2-s2.0-50849096413 | en_HK |
dc.identifier.hkuros | 163438 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-50849096413&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 26 | en_HK |
dc.identifier.issue | SUPPL. 12 | en_HK |
dc.identifier.spage | M60 | en_HK |
dc.identifier.epage | M70 | en_HK |
dc.identifier.isi | WOS:000260323100008 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Tay, SK=16147332800 | en_HK |
dc.identifier.scopusauthorid | Ngan, HYS=34571944100 | en_HK |
dc.identifier.scopusauthorid | Chu, TY=7401775698 | en_HK |
dc.identifier.scopusauthorid | Cheung, ANY=54927484100 | en_HK |
dc.identifier.scopusauthorid | Hseon Tay, E=24758858400 | en_HK |
dc.identifier.issnl | 0264-410X | - |